Virological characteristics of the SARS-CoV-2 JN.1 variant

Spike protein mutation Leu455Ser is a hallmark mutation of JN.1: we have recently shown that HK.3 and other flip variants carry Leu455Phe, which contributes to increased transmissibility and immune escape ability compared with the parental EG.5.1 variant.5 Here, we investigated the virological prope...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The Lancet infectious diseases 2024-02, Vol.24 (2), p.e82-e82
Hauptverfasser: Kaku, Yu, Okumura, Kaho, Padilla-Blanco, Miguel, Kosugi, Yusuke, Uriu, Keiya, Hinay, Jr, Alfredo A, Chen, Luo, Plianchaisuk, Arnon, Kobiyama, Kouji, Ishii, Ken J, Zahradnik, Jiri, Ito, Jumpei, Sato, Kei
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Spike protein mutation Leu455Ser is a hallmark mutation of JN.1: we have recently shown that HK.3 and other flip variants carry Leu455Phe, which contributes to increased transmissibility and immune escape ability compared with the parental EG.5.1 variant.5 Here, we investigated the virological properties of JN.1. KJI and KS are supported in part by AMED SCARDA Japan Initiative for World-leading Vaccine Research and Development Centers UTOPIA and by AMED SCARDA Program on R&D of new generation vaccine including new modality application. KS received funding from the AMED Research Program on HIV/AIDS, JST CREST, JSPS Core-to-Core Program, The Tokyo Biochemical Research Foundation, and The Mitsubishi Foundation; received consulting fees from Moderna Japan and Takeda Pharmaceutical; and honoraria for lectures from Gilead Sciences, Moderna Japan, and Shionogi & Co. JI received funding from JST PRESTO and JSPS KAKENHI Grant-in-Aid for Early-Career Scientists; and received consulting fees and honoraria for lectures from Takeda Pharmaceutical.
ISSN:1473-3099
1474-4457
DOI:10.1016/S1473-3099(23)00813-7